Welcome to our dedicated page for Elutia news (Ticker: ELUT), a resource for investors and traders seeking the latest updates and insights on Elutia stock.
Elutia Inc. develops and commercializes drug-eluting biomatrix products designed to improve compatibility between implanted medical devices and patients. Company news commonly covers financial results, product revenue from SimpliDerm and cardiovascular products, and development updates for NXT-41 and NXT-41x biomatrix technologies used in surgical reconstruction and related applications.
Recurring updates also include regulatory-process disclosures, commercial planning for plastic and reconstructive surgery, management presentations, equity compensation actions, and Nasdaq listing-compliance matters for Elutia's Class A common stock. The company's communications often connect its biomatrix platform with implant-based breast reconstruction, post-surgical infection reduction, and broader surgical-support use cases.
Elutia (Nasdaq: ELUT) completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics for up to $11 million, including $8 million in cash at closing and up to $3 million in contingent milestone payments over 18 months.
According to Elutia, the non-dilutive proceeds strengthen its balance sheet and allow a sharper strategic focus on NXT-41x, an antibiotic-eluting biomatrix for plastic and reconstructive surgery. The company expects FDA clearance for NXT-41x in the first half of 2027 and believes existing funding will support operations through the first full year of its commercial launch in 2028.
Elutia (Nasdaq: ELUT) reported second quarter 2026 results and outlined funding and timelines for its NXT-41/NXT-41x programs. The company secured up to $26 million of additional non-equity capital: a $15 million credit facility (including $10 million already funded and $5 million contingent on NXT-41x FDA clearance) and up to $11 million from the signed SimpliDerm divestiture. Elutia also expects release of $8 million in BioEnvelope escrow in 4Q 2026, and cites up to $34 million of additional cash from signed transactions.
An independent blinded survey of 50 plastic surgeons showed strong interest in NXT-41x, with 96% interested in adopting it and 92% willing to support hospital committee approval. Elutia continues to expect FDA clearance decisions for NXT-41 in 4Q 2026 and NXT-41x in 1H 2027, with a soft launch in 2H 2027 and full commercial launch in 2028. Q2 2026 net sales were $2.4 million versus $2.7 million a year ago; GAAP gross margin was 59.6%, adjusted gross margin 70.7%, and net loss from continuing operations $7.6 million. Cash and cash equivalents were $19.9 million at June 30, 2026.
Elutia (Nasdaq: ELUT) entered into a $15 million growth capital loan financing with Avenue Capital Group to support development and commercialization of NXT-41x, its next-generation antibiotic-eluting biomatrix for plastic and reconstructive surgeries. According to Elutia, $10 million was funded at closing, with a second $5 million tranche available upon FDA 510(k) clearance of NXT-41x.
NXT-41x is aimed at reducing post-operative infection rates, which the company notes can be as high as 15–20% in complex plastic and reconstructive procedures, including breast reconstruction. Elutia estimates a $1.5 billion U.S. market opportunity and anticipates FDA clearance in the first half of 2027, positioning this financing to help fund a future commercial launch.
Elutia (Nasdaq: ELUT) will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026. Management will host a conference call and webcast at 5:00 p.m. Eastern / 2:00 p.m. Pacific, accessible via online registration and through the Investors section of Elutia’s website.
Elutia (Nasdaq: ELUT) signed a definitive agreement to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics for total consideration of up to $11 million. Elutia is expected to receive $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 months.
According to Elutia, closing is expected in the second half of 2026, subject to customary conditions. The divestiture completes its strategic process for SimpliDerm and is intended to focus resources on NXT-41x, its next-generation antibiotic-eluting biomatrix, and to provide non-dilutive capital ahead of a targeted 2027 commercial launch.
Elutia (Nasdaq: ELUT) announced that CEO Dr. Randy Mills and CSO Dr. Michelle Williams will present at the Planet MicroCap Showcase 2026 at the Bellagio in Las Vegas on June 17–18, 2026.
The June 17 presentation at 2:00 pm PT will cover Elutia’s drug-eluting biomatrix technology aimed at reducing post-surgical infection in implant-based breast reconstruction following mastectomy. A live webcast and company video will be available, and the company will host one-on-one investor meetings during the event.
Elutia (Nasdaq: ELUT) granted inducement equity awards on May 13, 2026, under its 2026 Inducement Award Plan to one new employee, consistent with Nasdaq Listing Rule 5635(c)(4).
The grant consists of 48,000 non-qualified stock options at an exercise price of $1.05 per share, with four-year time-based vesting.
Elutia (Nasdaq: ELUT) reported Q1 2026 results and operational progress. Net sales from continuing operations were $3.1 million, up 6% year over year, with GAAP gross margin of 57.9% and adjusted gross margin of 66.5%. Net loss from continuing operations was $7.9 million.
Cash and escrowed funds totaled $36.5 million. FDA review of NXT-41 is advancing, with anticipated 510(k) clearance in Q4 2026 and NXT-41x in the first half of 2027. A new automated manufacturing platform is expected to support gross margins above 80% for NXT-41x. Strategic processes for SimpliDerm and the Cardiovascular line are ongoing.
Elutia (Nasdaq: ELUT) announced that CEO Dr. Randy Mills and CFO Matt Ferguson will present at the 16th Annual LD Micro Invitational on May 18, 2026, at the Luxe Sunset Boulevard Hotel in Los Angeles.
Management will discuss Elutia’s drug-eluting biomatrix technology for implant-based breast reconstruction and its role in addressing post-surgical infection, a leading cause of complications and revision surgeries. The presentation begins at 11:30 a.m. Pacific Time and will be available via live webcast. Elutia will also host one-on-one investor meetings on May 18, 2026.
Elutia (Nasdaq: ELUT) will report first quarter 2026 financial results after market close on Thursday, May 14, 2026. Management will host a live conference call and webcast the same day at 5:00 p.m. ET / 2:00 p.m. PT. Registration is required for dial-in and PIN.
A live and archived webcast will be available in the Investors section at http://investors.elutia.com/.